Our patent-pending technology was designed for testing hundreds of antigens in parallel without accepting a compromise on the performance of any single parameter. There is no restriction in the nature of the antigenic preparations.
Our core technology is based on a two-phased manufacturing process. While other multi-parameter ELISA assay use identical settings for the immobilisation of all antigens, we can adjust these conditions for each antigen individually, until the optimal result is obtained.
In the first step, antigens are coupled to activated nano-particles. This allows for individual and combinatorial optimization of each antigen coupling process. Each antigen is attached reflecting its biochemical properties and specific requirements for stability, which preserves the full epitope complexity of the source preparation.The nanoparticles multiply the surface of the solid phase presenting the antigen during the immunoassay, thereby enabling highly sensitive detection.
In the second step, the antigen-bearing nanoparticles are deposited contact free onto a solid phase matrix, forming a macroscopic array of individual assay parameters.
While requiring barely more serum than a miniaturized microarray test, the analytic performance can be greatly increased in terms of assay sensitivity and total precision.
The ALEX assay protocol integrates a powerful Cross-reactive Carbohydrate Deteminants (CCDs) inhibitor during serum incubation, which will clear up your speciﬁc IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the speciﬁ city of our test results.
The quantification is based on colorimetric or luminescence image acquisition, using CMOS sensors and instrumentation significantly cheaper than confocal laser scanners.